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Objective: To evaluate the inﬂuence of morcellation during surgery on clinical outcome in unexpected
early uterine leiomyosarcomas (LMSs) using a tumor-size-matched comparison study.
Materials and methods: We retrospectively reviewed the clinicopathological characteristics, prognostic
factors, and treatment outcomes of patients with Stage 1 uterine LMS from April 1993 to April 2014 in a
university-based tertiary hospital. Patients who received morcellation via abdomen, vagina, or laparos-
copy were compared with tumor-size-matched patients who underwent total hysterectomy without
morcellation.
Results: In total, 34 consecutive patients were identiﬁed, including 14 patients with morcellation and 20
patients without morcellation. There were no signiﬁcant difference between the two groups of patients
in age, parity, mitotic count, lymph node dissection, and adjuvant therapy. Six (42.9%) patients with
morcellation were reoperated at 18.5 days after the initial surgery. Tumor recurrence rates at local and
distant sites showed no difference between the two groups of patients. Patients with morcellation had a
marginally lower disease-free survival (DFS) and overall survival (OS) rates compared with patients
without morcellation. In univariate analysis, morcellation was marginally signiﬁcantly associated with
lower DFS [hazard ratio (HR), 2.62; 95% conﬁdence interval, 0.89e7.71; p ¼ 0.08] and OS (HR, 2.70; 95%
conﬁdence interval, 0.89e8.20; p ¼ 0.08). In multivariate analysis, morcellation was associated with
lower OS in marginal signiﬁcance (HR, 2.94; 95% conﬁdence interval, 0.83e10.39; p ¼ 0.09).
Conclusion: Tumor morcellation did not increase the abdominalepelvic recurrence rate, but may be
associated with lower DFS and OS in Stage 1 LMS.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Uterine leiomyosarcoma (LMS) is a rare disease with an annual
incidence of 0.4e0.64/100,000 women [1,2] and accounts for 1e2%
of uterine cancer cases [3]. It is a highly aggressive tumor with a
high recurrence rate, and complete surgical resection is the only
established curative treatment available [4]. At present, none of the
available imaging techniques could differentiate LMS from myoma
before surgery [5,6]. Consequently, LMSs are usuallys and Gynecology, National
South Road, Taipei 10002,
bstetrics & Gynecology. Publishedunderdiagnosed, and treated through myomectomy or minimally
invasive surgeries.
The safety of intratumor dissection or using amorcellator during
hysteroscopic or laparoscopic myomectomies or hysterectomies
has been of great concern [7]. Disruption of unexpected LMS during
surgery could cause tumor tissue dissemination, resulting in poor
patient survival outcome [8]. However, patient survival in early
LMS can be inﬂuenced by several factors [9]. Size of LMS is one of
the major factors that can affect patient outcome [9,10]. It has
previously been reported that tumor size outweighed the risk of
morcellation in causing poor patient survival in early LMS [11]. In
this study, we included all Stage 1 LMS patients who received
hysterectomy during the study period. Clinical outcomes were
compared between patients who received morcellation and tumor-
size-matched patients who were operated without morcellation.by Elsevier Taiwan LLC. All rights reserved.
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uate the inﬂuence of morcellation procedures on clinical outcome
in unexpected early stage LMS. Previous studies that evaluated the
impact of morcellation on survival outcome in early LMS were also
presented for comparison.
Materials and methods
Patients
All constitutive patients with Stage 1 uterine LMS operated in our
institute between April 1993 and April 2014 were retrospectively
included.Demographic andclinical datawere collected frommedical
records and pathological reports including patient age, parity, oper-
ative procedure, size of tumor, mitotic counts, timing, and surgical
procedures carried out (operation, reoperation, and postoperative
adjuvant therapy). Follow-up data including tumor recurrence,
anatomical location of tumor recurrence, and patient outcomewere
recorded. Pathological slides were reviewed by two experienced
pathologists. Patients were divided into the following two groups:
those who underwent total hysterectomy without morcellation
(nonmorcellation group) and those who underwent surgery
including abdominal, vaginal, and laparoscopic morcellation (mor-
cellation group). Only cases in the nonmorcellated group that were
matched with tumor size in the morcellated group were included.
This study was conducted with approval from the Institutional
Review Board at The National Taiwan University College of Medi-
cine (Taipei, Taiwan).
Statistical analysis
Parametric continuous variables were compared using a t test
for independent samples. Nonparametric dichotomous variables
were compared using Chi-square or Fisher exact tests. Survival time
was recorded from the date of operation to the date of death from
disease or the date of censor. KaplaneMeier analysis with a log-
ranking test was used to estimate survival probabilities and
compare survival distributions stratiﬁed by operative procedures
with or without morcellation. Univariate and multivariate regres-
sion analyses based on a Cox proportional hazard model were used
to evaluate the relative importance of variables as predictors of
survival time. The statistical analysis was carried out using the
Statistical Analysis System (SAS) version 8.0 (SAS Institute, Cary, NC,
USA). All p values less than 0.05 were considered statistically
signiﬁcant.
Results
A total of 43 patients were included in this study. There were 14
patients in the morcellation group and 29 in the nonmorcellationTable 1
Demographic and clinical variables (n ¼ 34).
Morcellation gro
Age (y) 49.7 ± 6.2 (42e6
Parity 1.6 ± 1.3 (0e4)
Tumor size (cm) 7.3 ± 2.9 (3e13)
Lymph node dissection 5 (35.7)
Ovarian preservation 6 (42.9)
Mitotic count
Low (<10/10 hpf) 2
High (10/10 hpf) 7
Reoperation 6 (42.9)
Period between initial operation and reoperation (d) 18.5 ± 20.6 (7e6
Values are presented as mean ± standard deviation (range) or number (percentage).
hpf ¼ high-power ﬁeld.group. After matching the tumor size, there were 20 patients in the
nonmorcellation group; thus, the total number of patients evalu-
ated in this study was 34. Demographic and clinical variables of the
two groups of patients are presented in Table 1. Tumor sizes be-
tween the two size-matched groups of patients were 8.9 cm in the
nonmorcellation group and 7.3 cm in the morcellation group. There
were no between-group differences in age, parity, lymph node
dissection, ovarian preservation, and mitotic count. In the morcel-
lation group, eight patients underwent laparoscopic-assisted
vaginal hysterectomy and six patients received myomectomy:
two via abdominal, two via laparoscopic, and two via hysteroscopic
approaches. All patients who received myomectomy were reoper-
ated at 7e60 days (median 18.5 ± 20.6 days) after the initial sur-
gery. One patient in the nonmorcellation group received lymph
node dissection (staging surgery) at 16 days after the initial surgery.
Surgical and adjuvant managements and patient outcomes are
presented in Table 2. Four patients in the morcellation group and
ﬁve patients in the nonmorcellation group completed the staging
procedure. None of the patients was upstaged after the reoperation
or staging surgery. Postoperative adjuvant therapies were pre-
scribed in 20 (58.8%) patients. There were no differences in adju-
vant therapy, such as radiotherapy and chemotherapy, between the
two groups. The median and mean follow-up periods were 24 and
33 (range, 12e99) months for the morcellation group, and 34 and
80 (range, 1e248) months for the nonmorcellation group, respec-
tively. Tumor recurred in eight (57.1%) patients in the morcellation
group and in six patients (30%) in the nonmorcellation group. The
number and types of morcellation procedures carried out, along
with the number of patients who experienced tumor recurrence
following the procedure are as follows: eight patients received
laparoscopic hysterectomies, with recurrence in six; two patients
received myomectomies, with recurrence in one; and two patients
received hysteroscopic myomectomies, with recurrence in one.
Pelvic recurrence occurred in three (21%) patients in the morcel-
lation group and in two patients (10%) in the nonmorcellation
group. In the morcellation group, pelvic recurrence occurred in two
patients who initially received laparoscopic hysterectomies and in
one patient after myomectomy. There was no cancer recurrence in
the two patients who initially received laparoscopic myomectomy.
No signiﬁcant differences were found between the two groups of
patients in tumor recurrence rates, location of recurrence, and
patient outcomes at the time of analysis.
Figs. 1 and 2 show the disease-free survival (DFS) and overall
survival (OS) relative to tumor morcellation in patients with Stage 1
LMS. The 3-year OS rate was 39.0% for patients in the morcellation
group and 80.1% for patients in the nonmorcellation group. The 5-
year OS rate was 19.5% for patients in the morcellation group and
53.4% for patients in the nonmorcellation group. Results of Cox
proportional regression analysis indicated that tumor morcellation
was found to be associated with poor survival rate, but had only aup (n ¼ 14) Nonmorcellation group (n ¼ 20) p
0) 52.7 ± 11.4 (39e80) 0.38
2.0 ± 1.2 (0e4) 0.37
8.9 ± 3.2 (4.5e14) 0.15
5 (25) 0.70
5 (25) 0.46
5
12 1.0
1 (5) 0.01
0) 16
Fig. 1. Disease-free survival relative to tumor morcellation in patients with Stage 1
leiomyosarcoma.
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tion were 2.62 and 2.70 in DFS and OS, respectively. In multivariate
analyses, when age, tumor size, and mitosis index were adjusted,
the HR of tumor morcellation was 2.94 in OS (Table 3).
Four literature reports (retrospective comparison studies) on
the clinical impact of morcellation during pelvic surgeries are listed
in Table 4 for comparison. Tumor size of LMS was not described in
two studies [12,13]. In the other study, the nonmorcellation group
showed signiﬁcantly larger tumor size compared with the mor-
cellation group [14]. In our study, we did not ﬁnd a higher rate of
pelvic and abdominal recurrence in the morcellation group
compared with the nonmorcellation group.
Discussion
A previous study evaluated the effect of morcellation on patient
outcome in early LMS and reported that tumor size outweighed
morcellation and was more signiﬁcant than morcellation in pre-
dicting poor patient survival [11]. However, patients with huge
myomatous nodules were commonly not approached by minimal
invasive surgery due to technical limitations. Therefore, we
designed this tumor-size-matched comparison study. In this study,
we demonstrated that morcellation may be associated with poorer
survival outcome in unexpected Stage 1 LMS.
Morcellation during surgery could cause dispersion of tissue
fragments into the peritoneal cavity. Complications were unlikely
to occur in benign myomatous lesions [15]. However, morcellation
in malignant conditions, such as LMS, was associated with higher0.00
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Fig. 2. Overall survival relative to tumor morcellation in patients with Stage 1
leiomyosarcoma.recurrence of sarcomatous lesions in the port sites, the pelvic and
the abdominal cavities, and subsequently with poor patient sur-
vival [8,16e19]. The occurrence of LMS during uterine morcellation
is uncommon. Only one case of unexpected LMS was found in 1091
cases undergoing uterine morcellation, and recurrence occurred in
four of the seven cases of LMS during second-look laparoscopy after
morcellation [20]. Literature reports on subsequent outcomes of
morcellation in unexpected LMS were very few and all of them
were single case reports or small series, case study reports. There
are four retrospective comparison studies that reported on the ef-
fect of tumor morcellation in localized LMS (Table 4). Three studies
demonstrated that tumor morcellation increased overall and local
recurrence rates, and worsened survival outcome [12e14]. How-
ever, one study stated that morcellation in LMS had no differences
in cancer recurrence rates and survival rates compared with cases
without morcellation [21]. Multiple factors, such as tumor stage,
cervical involvement, tumor size, histological grade, mitotic index,
and patient age at diagnosis were important and could affect the
prognosis of LMS [22]. In these studies, a lot of such survival-related
data were either missing or varied widely between the two study
groups. Stages were not synchronized. Tumor stage was either not
stated [21] or patients beyond Stage 1 were included. Two (6.5%)
patients in the nonmorcellation group and one (4.0%) patient in the
morcellation group had cervical involvement (Stage 2) [14]. Five
(13.5%) patients in the total abdominal hysterectomy group were at
Stage 2 or 3 [13]. Tumor size was not stated in three studies
[12,13,21]. In the only study that reported tumor size, the non-
morcellation group showed signiﬁcantly larger tumor size
compared with the morcellation group [14]. The morcellation
group included 76% of patients with tumor sizes less than 8 cm [14].
Histological grades and mitotic indexes were only stated in two
studies [13,14]. Patients in the morcellation group were signiﬁ-
cantly younger [13]. All these differences among the studies could
affect treatment outcome. Patients included in our study were all at
Stage 1. Patients in the nonmorcellation group were slightly
younger than those in the morcellation group, but there was no
signiﬁcant difference in age. Tumor size was matched between the
two groups of patients. Factors that could probably inﬂuence sur-
vival outcome were similar between the two groups of patients.
Tumor size is an important prognostic factor for LMS patients. In
the 2009 International Federation of Gynecology and Obstetrics
staging classiﬁcation, Stage 1 LMS was subdivided into Ia and Ib
using 5 cm as a cutoff point. Tumor size used as a risk-stratiﬁcation
prognostic factor in early LMS was well validated in several studies
[9,23]. The 5-year survival rate for Stage Ia and Ibwas reported to be
76.6% and 48.4%, respectively [9]. The median survival period for
Stage Ia was more than 20 years, and was 5.3 years in Stage Ib [23].
Slight difference in tumor size in small series, case study reports
could cause a large difference in survival outcome. In a previous
study that included nonmorcellation patients with signiﬁcantly
larger tumor size than the morcellation patients, there was no
signiﬁcant effect of morcellation on patient survival [11] (Table 4).
In this tumor-size-matched study, wewere able to demonstrate the
impact of morcellation on poor patient outcome. Likewise, various
differences in the other outcome-related factors between the two
study groups could inﬂuence the impact of morcellation. Studies on
the survival outcome of LMS after morcellation need careful
interpretation.
LMS is a rapid-growing tumor and occult metastasis could occur
at presumed localized lesions. In presumed Stage 1 LMS, imaging
studies after postoperative morcellation showed upstaging in one
of ﬁve, and in two of 15 cases [24,25]. Our patients reported in
Table 4 were not upstaged after postoperative imaging studies.
Complete staging surgery during initial operation or at immediate
second-look operation is helpful to identify the spread of occult
Table 2
Surgical treatment, adjuvant management, and survival outcome.
Morcellation
group (n ¼ 14)
Nonmorcellation
group (n ¼ 20)
p
Procedure performed at initial operation
Total abdominal hysterectomy 0 20
Bilateral salpingo-oophorectomy 3 15
Pelvic lymph node dissection 0 4
Vaginal total hysterectomy 0 1
Laparoscopic-assisted vaginal
hysterectomy
8 0
Myomectomy 2 0
Laparoscopic myomectomy 2 0
Hysteroscopic myomectomy 2 0
Procedure performed at reoperation
Total abdominal hysterectomy 6 0
Bilateral salpingo-oophorectomy 5 0
Pelvic lymph node dissection 4 1
Adjuvant therapy
None 3 (21.4) 11 (55) 0.15
Radiotherapy 6 (42.9) 5 (25)
Chemotherapy 5 (35.7) 4 (20)
Recurrence
No 6 (42.9) 14 (70) 0.16
Yes 8 (57.1) 6 (30)
Recurrence location
Abdomen/pelvis 3 (21.4) 2 (10) 0.63
Distant 5 (35.7) 6 (30) 1.00
Both 0 2 (10) 0.50
Outcome
Alive 6 (42.9) 14 (70) 0.19
Alive with disease 1 (7.1) 0
Dead 7 (50.0) 6 (30)
Values are presented as number (percentage).
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of 59 cases of early stage LMS, complete staging surgery revealed
3.5% lymph node metastases, 3.5% adnexal metastases, 5.3% posi-
tive peritoneal cytology, and eight (13.6%) patients were upstaged
[26]. Complete staging was performed in 26.5% of our patients: four
in the nonmorcellation group during initial surgery and ﬁve at the
immediate second-look operation. Park et al [14] reported com-
plete staging surgery in 23.9% of their patients, six (2 in the non-
morcellation group and 4 in the morcellation group) at initial
surgery and ﬁve at immediate second-look operation. All of these
patients were not upstaged.
Peritoneal cancer spreading was observed at immediate second-
look operation. Oduyebo et al [25] reported intra-abdominal and
pelvic peritoneal disease in two of 15 patients at immediate
second-look operation after tumor morcellation. Higher rate of
peritoneal spreading occurred in delayed second-look operation.
Einstein et al [24] reported that two of their ﬁve patients experi-
enced peritoneal spreading at an interval of 41e132 days after
initial morcellation. Macroscopic peritoneal spreading was detec-
ted at immediate second-look operation andmicroscopic spreading
could be deleted at a later period. Park et al [14] reported no
peritoneal tumor spreading when reoperation was performed in
seven patients (1 in the nonmorcellation group and 6 in theTable 3
Survival analysis in patients with Stage 1 leiomyosarcoma.
Variables Univariate analysis
Disease-free survival Overall survi
HR (95% CI) p HR (95% CI)
Morcellation (yes vs. no) 2.62 (0.89e7.71) 0.08 2.70 (0.89e8.20)
Multivariate analysis was performed when age, tumor size, and mitotic count were adju
CI ¼ conﬁdence interval; HR ¼ hazard ratio.morcellation group) immediately after initial surgery. Similarly, we
performed immediate reoperation at an interval of 7e60 days after
initial morcellation in seven patients (1 in the nonmorcellation
group and 6 in themorcellation group) and also did not observe any
peritoneal spreading. At a longer follow-up period, patients in the
morcellation group were reported to have higher intra-abdominal
and pelvic recurrence rates than those in the nonmorcellation
group [12e14]. However, Morice et al [21] did not report a similar
ﬁnding, and we also found no differences in the intra-abdominal
and pelvic recurrence rates between the two groups of patients.
The main site of ﬁrst recurrence in LMS patients was found to be
the extra-pelvic region, whereas the lungs were reported to be the
most common site of recurrence [27,28]. All of our patients with
distant recurrence showed lung metastasis. The recurrence rate in
the pelvic cavity is reported in the range of 6e19% at median
follow-up periods of 16e42 months for traditional open surgery
[28,29]. The rate of pelvic recurrence increased with time and could
be as high as 75% among the survivors at 10 years after surgery [30].
The very high pelvic recurrence rate after morcellation as reported
by George et al [13] and Park et al [14] is a major reason for poor
survival outcome in their study patients.
It is likely that application of different morcellation techniques
could be the reason behind the varying incidence of peritoneal
spreading at immediate surgery and during the follow-up period.
Patients in the morcellation group received a combination of
various types of morcellation procedures. Surgical methods per-
formed by different operators were different in similar types of
operations. Tumor injury could also occur in the nonmorcellation
group. Perri et al [12] reported tumor recurrence in two of four
patients who had sharp instrument injury during traditional
abdominal hysterectomy. In cases involving larger tumors, the
chance of tumor penetration and rupture during operation is
higher. However, such operative details could not be extracted
retrospectively from operative notes. It is interesting that tumor
recurrence did not occur in two patients who received laparoscopic
myomectomy in this study. Tumor sizes were 4 cm and 9.6 cm in
these two patients and theywere followed up for 13months and 32
months, respectively. We used the in situmorcellation technique in
our laparoscopic myomectomy [31] and this method might cause
lesser tumor spreading during operation. However, more number
of cases are needed to conﬁrm this observation.
In addition, tissues that were extracted from mini-invasive
surgeries were difﬁcult for surgical staging. Tumor sizes were ob-
tained from preoperative sonographic images. When multiple ﬁ-
broids were detected, the biggest one was presumed to be the one
with LMS and this might not be true.
The approach of applying adjuvant therapy after LMS operation
varied among studies. Beneﬁts of adjuvant therapies, such as
radiotherapy or chemotherapy, after LMS surgery on survival
outcome were inconsistent [27]. Results of this study and those of
Perri et al [12] provided more, whereas George et al [13] and Park
et al [14] provided less adjuvant therapies to patients after mor-
cellation compared with patients without morcellation. The cur-
rent study and that of Perri et al [12] used radiotherapy as themajorMultivariate analysis
val Disease-free survival Overall survival
p HR (95% CI) p HR (95% CI) p
0.08 2.43 (0.70e8.40) 0.16 2.94 (0.83e10.39) 0.09
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K.-H. Lin et al. / Taiwanese Journal of Obstetrics & Gynecology 54 (2015) 172e177176type of adjuvant therapy. By contrast, Park et al [14] and George
et al [13] chose chemotherapy in their studies. Although all studies
showed higher distant recurrence rates in the morcellation group,
our study showed no signiﬁcant higher pelvic/abdominal recur-
rence rate in the morcellation group compared with the non-
morcellation group. Radiotherapy after surgery was reported to be
associated with decreased local recurrence rate in early stage LMS
[28]. It could be possible that using radiotherapy as adjuvant
therapy might cause less microscopic peritoneal spreading after
morcellation and decreased subsequent pelvic and abdominal
recurrence.
There are some other limitations in the study. The number of
cases analyzed was too small and the follow-up period for the
morcellation group was relatively too short. Although we tried to
match tumor size in our study, other factors could not be matched
among studies.
In conclusion, our study demonstrated that apart from the effect
of morcellation, several factors could affect the survival of patients
in early stage LMS. Among these factors, tumor size is the major
factor and by tumor-size-matched comparison study, morcellation
appeared to be associated with a worse prognosis in Stage 1 LMS.
Therefore, caution should be applied while using intraperitoneal
morcellation.Conﬂicts of interest
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